A collection of timely studies, quizzes and cases and the latest news in Ovarian Cancer
Article: Seclidemstat May Improve ICI Response in Some Ovarian Cancers
Immune checkpoint inhibitor (ICI) therapy can unleash the immune system to fight cancer. Yet the majority of patients do not respond to ICIs. And even then, many patients relapse, undermining the promise of these therapies.
A 54- year- old African- American woman was diagnosed with stage IIIC high- grade serous ovarian 24 months ago. After an exploratory laparotomy resulted in successful resection of all gross disease, she received six cycles of intravenous paclitaxel/ carboplatin with a resultant clinical complete remission. She now presents with a rising CA- 125 (three successive monthly elevated values with the last value at 360 U/ ml). She is asymptomatic. A CT scan of the abdomen/ pelvis shows no evidence of recurrent disease. Which of the following would you recommend at this point?
Download an excerpt from the Bethesda Handbook of Clinical Oncology, a comprehensive review of the management of ovarian cancer, emphasizing practical information that can be applied in everyday in fast-moving patient care situations.
Article: Tumor Gene Test Shows Promise of Better Predicting Ovarian Cancer Survival
Survival rates among women with ovarian cancer vary greatly, making the ability to determine who potentially faces a more aggressive form of the disease challenging for oncologists. Determined to find a better way to predict ovarian cancer survival rates than stage and age, a team of researchers recently developed a tumor gene test and found that the results offered improved prediction rates.
This illustrated chart on ovarian cancer is a user-friendly, downloadable handout that explains ovarian cancer in easy-to-understand language. Learn about risk factors, signs and symptoms, diagnosis, treatment options, and prevention strategies.
A 40- year-old woman presents to her gynecologist because her sister, aged 42, was recently diagnosed with serous ovarian carcinoma and she was found to carry a deleterious germline BRCA1 mutation. The patient reports a strong family history of both breast and ovarian cancer, also including her mother (breast cancer). Testing reveals that she also carries the deleterious BRCA1 mutation. She has completed child-bearing. Which of the following would you recommend?